VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine
Vaccine Information
  • Vaccine Name: T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine
  • Target Pathogen: Toxoplasma gondii
  • Target Disease: Toxoplasmosis
  • Vaccine Ontology ID: VO_0011521
  • Type: Subunit vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: mouse
  • Rop2 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Immunization Route: Footpad Injection
Host Response

Mouse Response

  • Host Strain: Balb/c, C57BL/6 and C3H
  • Vaccination Protocol: The immunization doses and boosters of each antigen were the following: Rop2 (44 kDa, 2 μg), LiHsp83 (86 kDa, 6 μg), Rop2-LiHsp83 (not, vert, similar120 kDa, 9 μg) and the mixture of Rop2 and LiHsp83 (2 + 6 μg, respectively). Balb/c, C57BL/6 and C3H mice were immunized by footpad injections on days 0, 21, 35 and 45 with PBS (control) or recombinant proteins (Echeverria et al., 2006).
  • Challenge Protocol: To analyze protection against virulent T. gondii strain (lethal challenge) immunized mice were challenged intraperitoneally with 10^5 T. gondii RH tachyzoites 2 weeks after the last immunization. To analyze protection against non-lethal challenge, immunized mice were orally infected with 20 cysts of the ME49 T. gondii strain 2 weeks after the last booster. The brain parasite load was evaluated 1 month after infection (Echeverria et al., 2006).
  • Efficacy: Vaccination with fusion protein conferred a remarkable resistance against oral infection with ME49 cysts in C57BL/6 and C3H mice, in comparison to mice immunized with Rop2 alone or the protein mixture. Following lethal challenge, a significant survival rate was observed in Rop2-83 immunized Balb/c and C57BL/6 mice in comparison to control groups (Echeverria et al., 2006).
References
Echeverria et al., 2006: Echeverria PC, de Miguel N, Costas M, Angel SO. Potent antigen-specific immunity to Toxoplasma gondii in adjuvant-free vaccination system using Rop2-Leishmania infantum Hsp83 fusion protein. Vaccine. 2006; 24(19); 4102-4110. [PubMed: 16545504].